Application No.: 09/313,628 Docket No.: H1890.0201/P201

COMPLETE LISTING OF CLAIMS

IN ASCENDING ORDER WITH STATUS INDICATOR

1 - 20 (Cancelled)

- 21. (Currently amended). A <u>In a method of achieving contraception in a premenopausal human female by administering to the female a contraception effective amount of a contraceptive agent, the improvement which comprises said agent being a combination of a contraception effective amount of a Selective Estrogen Receptor Modulator and an agent which exhibits progestogenic activity, wherein the amount of the agent which exhibits progestogenic activity is effective to modulate the <u>bleeding</u> side effects of the Selective Estrogen Receptor Modulator.</u>
- 22. (Previously added). The method of claim 21 wherein the Selective Estrogen Receptor Modulator is clomiphene.
- 23. (Previously added). The method of claim 21 wherein the Selective Estrogen Receptor Modulator is a benzothiophene.
- 24. (Previously added). The method of claim 21 wherein the agent which exhibits progestogenic activity is an antiprogestin.
- 25. (Previously added). The method of claim 24 wherein the antiprogestin is a progesterone receptor antagonist.

Application No.: 09/313,628

26. (Previously added). The method of claim 25 wherein the Selective Estrogen Receptor Modulator is clomiphene.

Docket No.: H1890.0201/P201

27. (Previously added). The method of claim 25 wherein the Selective Estrogen Receptor Modulator is a benzothiophene.

28. (Previously added). The method of claim 24 wherein the amount of antiprogestin is that sufficient to maintain the blood estrogen concentration in the range of about 25 to 125 pg/ml.

- 29. (Previously added). The method of claim 28 wherein the amount of antiprogestin is that sufficient to maintain the blood estrogen concentration in the range of about 60 to 90 pg/ml.
- 30. (Previously added). The method of claim 21 wherein the agent which exhibits progestogenic activity expresses both androgenic and progestogenic activity.
- 31. (Previously added). The method of claim 30 wherein the agent which exhibits progestogenic activity comprises the combination of an androgen and a progestin.
- 32. (Previously added). The method of claim 30 wherein the agent which exhibits progestogenic activity is a single material which expresses both activities.

Application No.: 09/313,628

Docket No.: H1890.0201/P201

33. (Previously added). The method of claim 32 wherein the agent which exhibits progestogenic activity is danazol or levonorgestrel.